کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5622831 | 1406192 | 2014 | 9 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Featured ArticleIncreased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels Featured ArticleIncreased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels](/preview/png/5622831.png)
BackgroundGiven the difficult clinical differential diagnosis between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), growing interest resulted in research on α-synuclein as a potential cerebrospinal fluid biomarker (CSF) for synucleinopathies.MethodsCSF α-synuclein-140 concentrations were determined by a prototype xMAP⢠bead-based assay (Innogenetics NV, Belgium). In addition, CSF amyloid β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau (P-tau181P) levels were determined.ResultsCSF α-synuclein levels were higher in AD patients as compared with cognitively healthy controls (P = .019) and patients with synucleinopathies (P < .001). CSF α-synuclein levels were correlated with T-tau (P < .001) and P-tau181P (P < .001) levels in autopsy-confirmed AD patients. A diagnostic algorithm using α-synuclein and P-tau181P discriminated neuropathologically confirmed AD from DLB patients, resulting in sensitivity and specificity values of 85% and 81%, respectively.ConclusionBecause CSF α-synuclein levels were significantly higher in AD as compared with synucleinopathies, α-synuclein might have a value as a biomarker for differential dementia diagnosis.
Journal: Alzheimer's & Dementia - Volume 10, Issue 5, Supplement, October 2014, Pages S290-S298